Progress toward personalized medicine for glaucoma

References

• Jonas JB, Dichtl A. Evaluation of the retinal nerve fiber layer. Surv. Ophthalmol.40(5), 369–378 (1996).
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Friedman DS, Fechtner RD et al. Risk assessment in the management of patients with ocular hypertension. Am. J. Ophthalmol.138(3), 458–467 (2004).
   PubMed Web of Science ®Google Scholar
• Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science291(5507), 1304–1351 (2001).
   PubMed Web of Science ®Google Scholar
• Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature409(6822), 860–921 (2001).
   PubMed Web of Science ®Google Scholar
• Clamp M, Fry B, Kamal M et al. Distinguishing protein-coding and noncoding genes in the human genome. Proc. Natl Acad. Sci. USA104(49), 19428–19433 (2007).
   PubMed Web of Science ®Google Scholar
• Consortium TIH. The International HapMap Project. Nature426(6968), 789–796 (2003).
   PubMed Web of Science ®Google Scholar
• Botstein D, Risch N. Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat. Genet.33(Suppl.), 228–237 (2003).
   PubMed Web of Science ®Google Scholar
• Kingsmore SF, Lindquist IE, Mudge J, Gessler DD, Beavis WD. Genome-wide association studies: progress and potential for drug discovery and development. Nat. Rev. Drug. Discov.7(3), 221–230 (2008).
   PubMed Web of Science ®Google Scholar
• Haines JL, Hauser MA, Schmidt S et al. Complement factor H variant increases the risk of age-related macular degeneration. Science308(5720), 419–421 (2005).
   PubMed Web of Science ®Google Scholar
• Klein RJ, Zeiss C, Chew EY et al. Complement factor H polymorphism in age-related macular degeneration. Science308(5720), 385–389 (2005).
   PubMed Web of Science ®Google Scholar
• Thorleifsson G, Magnusson KP, Sulem P et al. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science317(5843), 1397–1400 (2007).
   PubMed Web of Science ®Google Scholar
• McLaren NC, Moroi SE. Clinical implications of pharmacogenetics for glaucoma therapeutics. Pharmacogenomics J.3, 197–201 (2003).
   PubMed Web of Science ®Google Scholar
• Benichou J. Biostatistics and epidemiology: measuring the risk attributable to an environmental or genetic factor. C. R. Biol.330(4), 281–298 (2007).
   PubMed Web of Science ®Google Scholar
• Racette L, Wilson MR, Zangwill LM, Weinreb RN, Sample PA. Primary open-angle glaucoma in blacks: a review. Surv. Ophthalmol.48(3), 295–313 (2003).
   PubMed Web of Science ®Google Scholar
• Varma R, Mohanty SA, Deneen J, Wu J, Azen SP. Burden and predictors of undetected eye disease in Mexican-Americans: the Los Angeles Latino Eye Study. Med. Care46(5), 497–506 (2008).
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Khoury MJ, Drazen JM. Letting the genome out of the bottle – will we get our wish? N. Engl. J. Med.358(2), 105–107 (2008).
   PubMed Web of Science ®Google Scholar
• Geransar R, Einsiedel E. Evaluating online direct-to-consumer marketing of genetic tests: informed choices or buyers beware? Genet. Test.12(1), 13–23 (2008).
   PubMedGoogle Scholar
• Feero WG, Guttmacher AE, Collins FS. The genome gets personal – almost. JAMA299(11), 1351–1352 (2008).
   PubMed Web of Science ®Google Scholar
• Moroi SE, Richards JE. Glaucoma and genomic medicine. Glaucoma Today1, 16–24 (2008).
   Google Scholar
• Wiggs JL. Genetic etiologies of glaucoma. Arch. Ophthalmol.125(1), 30–37 (2007).
   PubMedGoogle Scholar
• Nemesure B, Jiao X, He Q et al. A genome-wide scan for primary open-angle glaucoma (POAG): the Barbados Family Study of Open-Angle Glaucoma. Hum. Genet.112(5–6), 600–609 (2003).
   PubMed Web of Science ®Google Scholar
• Vincent AL, Billingsley G, Buys Y et al. Digenic inheritance of early-onset glaucoma: CYP1B1, a potential modifier gene. Am. J. Hum. Genet.70(2), 448–460 (2002).
   PubMed Web of Science ®Google Scholar
• Wiggs JL, Allingham RR, Hossain A et al. Genome-wide scan for adult onset primary open angle glaucoma. Hum. Mol. Genet.9(7), 1109–1117 (2000).
   PubMed Web of Science ®Google Scholar
• Stoilov I, Akarsu AN, Sarfarazi M. Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum. Mol. Genet.6(4), 641–647 (1997).
   PubMed Web of Science ®Google Scholar
• Nouri-Mahdavi K, Hoffman D, Coleman AL et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology111(9), 1627–1635 (2004).
   PubMed Web of Science ®Google Scholar
• Lichter PR, Musch DC, Gillespie BW et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology108(11), 1943–1953 (2001).
   PubMed Web of Science ®Google Scholar
• Drance S, Anderson DR, Schulzer M; Collaborative Normal-Tension Glaucoma Study Group. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am. J. Ophthalmol.131(6), 699–708 (2001).
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol.120(10), 1268–1279 (2002).
   PubMed Web of Science ®Google Scholar
• Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Am. J. Ophthalmol.120(6), 718–731 (1995).
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol.120(6), 701–713; discussion 829–730 (2002).
   PubMed Web of Science ®Google Scholar
• Gordon MO, Beiser JA, Brandt JD et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch. Ophthalmol.120(6), 714–720; discussion 829–730 (2002).
   PubMed Web of Science ®Google Scholar
• Iyengar SK. The quest for genes causing complex traits in ocular medicine: successes, interpretations, and challenges. Arch. Ophthalmol.125(1), 11–18 (2007).
   PubMedGoogle Scholar
• Viswanathan AC, Hitchings RA, Indar A et al. Commingling analysis of intraocular pressure and glaucoma in an older Australian population. Ann. Hum. Genet.68(Pt 5), 489–497 (2004).
   PubMed Web of Science ®Google Scholar
• Bonomi L, Marchini G, Marraffa M et al. Prevalence of glaucoma and intraocular pressure distribution in a defined population. The Egna–Neumarkt Study. Ophthalmology105(2), 209–215 (1998).
   PubMed Web of Science ®Google Scholar
• Nemesure B, Honkanen R, Hennis A, Wu SY, Leske MC. Incident open-angle glaucoma and intraocular pressure. Ophthalmology114(10), 1810–1815 (2007).
   PubMed Web of Science ®Google Scholar
• Herndon LW. Measuring intraocular pressure-adjustments for corneal thickness and new technologies. Curr. Opin. Ophthalmol.17(2), 115–119 (2006).
   PubMed Web of Science ®Google Scholar
• Sarkisian SR Jr. An update on tonometry. Glaucoma Today4(6), 31–36 (2006).
   Google Scholar
• Armaly MF. The genetic determination of ocular pressure in the normal eye. Arch. Ophthalmol.78(2), 187–192 (1967).
   PubMedGoogle Scholar
• Levene RZ, Workman PL, Broder SW, Hirschhorn K. Heritability of ocular pressure in normal and suspect ranges. Arch. Ophthalmol.84(6), 730–734 (1970).
   PubMedGoogle Scholar
• Kalenak JW, Paydar F. Correlation of intraocular pressures in pairs of monozygotic and dizygotic twins. Ophthalmology102(10), 1559–1564 (1995).
   PubMed Web of Science ®Google Scholar
• Gottfredsdottir MS, Sverrisson T, Musch DC, Stefansson E. Chronic open-angle glaucoma and associated ophthalmic findings in monozygotic twins and their spouses in Iceland. J. Glaucoma8(2), 134–139 (1999).
   PubMed Web of Science ®Google Scholar
• Chang TC, Congdon NG, Wojciechowski R et al. Determinants and heritability of intraocular pressure and cup-to-disc ratio in a defined older population. Ophthalmology112(7), 1186–1191 (2005).
   PubMed Web of Science ®Google Scholar
• van Koolwijk LM, Despriet DD, van Duijn CM et al. Genetic contributions to glaucoma: heritability of intraocular pressure, retinal nerve fiber layer thickness, and optic disc morphology. Invest. Ophthalmol. Vis. Sci.48(8), 3669–3676 (2007).
   PubMed Web of Science ®Google Scholar
• Klein BE, Klein R, Lee KE. Heritability of risk factors for primary open-angle glaucoma: the Beaver Dam Eye Study. Invest. Ophthalmol. Vis. Sci.45(1), 59–62 (2004).
   PubMed Web of Science ®Google Scholar
• Parssinen O, Era P, Tolvanen A, Kaprio J, Koskenvuo M, Rantanen T. Heritability of intraocular pressure in older female twins. Ophthalmology114(12), 2227–2231 (2007).
   PubMed Web of Science ®Google Scholar
• Duggal P, Klein AP, Lee KE, Klein R, Klein BE, Bailey-Wilson JE. Identification of Novel Genetic Loci for Intraocular Pressure: a genomewide scan of the Beaver Dam Eye Study. Arch. Ophthalmol.125(1), 74–79 (2007).
   PubMedGoogle Scholar
• Rotimi CN, Chen G, Adeyemo AA et al. Genomewide scan and fine mapping of quantitative trait loci for intraocular pressure on 5q and 14q in West Africans. Invest. Ophthalmol. Vis. Sci.47(8), 3262–3267 (2006).
   PubMed Web of Science ®Google Scholar
• Monemi S, Spaeth G, DaSilva A et al. Identification of a novel adult-onset primary open-angle glaucoma (POAG) gene on 5q22.1. Hum. Mol. Genet.14(6), 725–733 (2005).
   PubMed Web of Science ®Google Scholar
• Charlesworth JC, Dyer TD, Stankovich JM et al. Linkage to 10q22 for maximum intraocular pressure and 1p32 for maximum cup-to-disc ratio in an extended primary open-angle glaucoma pedigree. Invest. Ophthalmol. Vis. Sci.46(10), 3723–3729 (2005).
   PubMed Web of Science ®Google Scholar
• Brubaker RF. Goldmann’s equation and clinical measures of aqueous dynamics. Exp. Eye Res.78(3), 633–637 (2004).
   PubMed Web of Science ®Google Scholar
• Brubaker RF. Clinical measurements of aqueous dynamics: implications for addressing glaucoma. In: The Eye’s Aqueous Humor, From Secretion to Glaucoma. Civan MM (Ed.). Academic Press, NY, USA, 234–284 (1998).
   Google Scholar
• Toris CB, Koepsell SA, Yablonski ME, Camras CB. Aqueous humor dynamics in ocular hypertensive patients. J. Glaucoma.11(3), 253–258 (2002).
   PubMed Web of Science ®Google Scholar
• Grant W. Tonographic method for measuring the facility and rate of aqueous flow in human eyes. Arch. Ophthalmol.44, 204–214 (1950).
   PubMedGoogle Scholar
• Selbach JM, Posielek K, Steuhl KP, Kremmer S. Episcleral venous pressure in untreated primary open-angle and normal-tension glaucoma. Ophthalmologica219(6), 357–361 (2005).
   PubMed Web of Science ®Google Scholar
• Orzalesi N, Rossetti L, Bottoli A, Fogagnolo P. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology113(2), 239–246 (2006).
   PubMed Web of Science ®Google Scholar
• Walters TR, DuBiner HB, Carpenter SP, Khan B, VanDenburgh AM. 24-hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv. Ophthalmol.49 (Suppl. 1), S26–S35 (2004).
   PubMed Web of Science ®Google Scholar
• Camras CB, Sheu WP. Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States. J. Glaucoma.14(2), 161–167 (2005).
   PubMed Web of Science ®Google Scholar
• Schuman JS. Effects of systemic β-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Ophthalmology107(6), 1171–1177 (2000).
   PubMed Web of Science ®Google Scholar
• Orzalesi N, Rossetti L, Bottoli A, Fumagalli E, Fogagnolo P. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch. Ophthalmol.121(4), 453–457 (2003).
   PubMed Web of Science ®Google Scholar
• Azuara-Blanco A, Burr J. The rising cost of glaucoma drugs. Br. J. Ophthalmol.90(2), 130–131 (2006).
   PubMed Web of Science ®Google Scholar
• Holmstrom S, Buchholz P, Walt J, Wickstrom J, Aagren M. The cost–effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries. Curr. Med. Res. Opin.22(5), 897–905 (2006).
   PubMed Web of Science ®Google Scholar
• Friedman DS, Quigley HA, Gelb L et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest. Ophthalmol. Vis. Sci.48(11), 5052–5057 (2007).
   PubMed Web of Science ®Google Scholar
• Sleath B, Robin AL, Covert D, Byrd JE, Tudor G, Svarstad B. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology113(3), 431–436 (2006).
   PubMed Web of Science ®Google Scholar
• Schmitt CJ, Lotti VJ, LeDouarec JC. Penetration of timolol into the rabbit eye. Measurements after ocular instillation and intravenous injection. Arch. Ophthalmol.98(3), 547–551 (1980).
   PubMed Web of Science ®Google Scholar
• Salminen L, Imre G, Huupponen R. The effect of ocular pigmentation on intraocular pressure response to timolol. Acta. Ophthalmol. Suppl.173, 15–18 (1985).
   PubMedGoogle Scholar
• Higginbotham EJ, Schuman JS, Goldberg I et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch. Ophthalmol.120(10), 1286–1293 (2002).
   PubMed Web of Science ®Google Scholar
• Salazar M, Shimada K, Patil PN. Iris pigmentation and atropine mydriasis. J. Pharmacol. Exp. Ther.197(1), 79–88 (1976).
   PubMed Web of Science ®Google Scholar
• Mansberger SL, Hughes BA, Gordon MO et al. Comparison of initial intraocular pressure response with topical β-adrenergic antagonists and prostaglandin analogues in African American and white individuals in the Ocular Hypertension Treatment Study. Arch. Ophthalmol.125(4), 454–459 (2007).
   PubMedGoogle Scholar
• Shin J, Johnson JA. Pharmacogenetics of β-blockers. Pharmacotherapy27(6), 874–887 (2007).
   PubMed Web of Science ®Google Scholar
• Edeki TI, He H, Wood AJ. Pharmacogenetic explanation for excessive β-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. JAMA274(20), 1611–1613 (1995).
   PubMed Web of Science ®Google Scholar
• Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure in the normal eye. Arch. Ophthalmol.96(11), 2045–2048 (1978).
   PubMed Web of Science ®Google Scholar
• Yablonski ME, Zimmerman TJ, Waltman SR, Becker B. A fluorophotometric study of the effect of topical timolol on aqueous humor dynamics. Exp. Eye Res.27(2), 135–142 (1978).
   PubMed Web of Science ®Google Scholar
• Wax MB, Molinoff PB. Distribution and properties of β-adrenergic receptors in human iris-ciliary body. Invest. Ophthalmol. Vis. Sci.28(3), 420–430 (1987).
   PubMed Web of Science ®Google Scholar
• Nathanson JA. Adrenergic regulation of intraocular pressure: identification of β2-adrenergic-stimulated adenylate cyclase in ciliary process epithelium. Proc. Natl Acad. Sci. USA77(12), 7420–7424 (1980).
   PubMed Web of Science ®Google Scholar
• Belfer I, Buzas B, Evans C et al. Haplotype structure of the β adrenergic receptor genes in US Caucasians and African Americans. Eur. J. Hum. Genet.13(3), 341–351 (2005).
   PubMed Web of Science ®Google Scholar
• McCarty CA, Burmester JK, Mukesh BN, Patchett RB, Wilke RA. Intraocular pressure response to topical β-blockers associated with an ADRB2 single-nucleotide polymorphism. Arch. Ophthalmol.126(7), 959–963 (2008).
   PubMedGoogle Scholar
• Inagaki Y, Mashima Y, Fuse N et al. Polymorphism of β-adrenergic receptors and susceptibility to open-angle glaucoma. Mol. Vis.12, 673–680 (2006).
   PubMed Web of Science ®Google Scholar
• McLaren N, Reed DM, Musch DC et al. Evaluation of the β2-adrenergic receptor gene as a candidate glaucoma gene in 2 ancestral populations. Arch. Ophthalmol.125(1), 105–111 (2007).
   PubMedGoogle Scholar
• Gungor K, Ozkur M, Cascorbi I et al. β2-adrenergic receptor polymorphism and susceptibility to primary congenital and primary open angle glaucoma. Eur. J. Clin. Pharmacol.59(7), 527–531 (2003).
   PubMed Web of Science ®Google Scholar
• Gungor K, Beydagi H, Bekir N et al. The impact of acute dynamic exercise on intraocular pressure: role of the β2-adrenergic receptor polymorphism. J. Int. Med. Res.30(1), 26–33 (2002).
   PubMed Web of Science ®Google Scholar
• Fuchsjager-Mayrl G, Markovic O, Losert D et al. Polymorphism of the β–2 adrenoceptor and IOP lowering potency of topical timolol in healthy subjects. Mol. Vis.11, 811–815 (2005).
   PubMed Web of Science ®Google Scholar
• Schwartz SG, Puckett BJ, Allen RC, Castillo IG, Leffler CT. β1-adrenergic receptor polymorphisms and clinical efficacy of Betaxolol hydrochloride in normal volunteers. Ophthalmology112(12), 2131–2136 (2005).
   PubMed Web of Science ®Google Scholar
• Dane S, Kocer I, Demirel H, Ucok K, Tan U. Long-term effects of mild exercise on intraocular pressure in athletes and sedentary subjects. Int. J. Neurosci.116(10), 1207–1214 (2006).
   PubMed Web of Science ®Google Scholar
• Musch DC, Gillespie BW, Niziol LM, Cashwell LF, Lichter PR. Factors associated with intraocular pressure before and during 9 years of treatment in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology115(6), 927–933 (2008).
   PubMed Web of Science ®Google Scholar
• Kang JH, Pasquale LR, Willett W et al. Antioxidant intake and primary open-angle glaucoma: a prospective study. Am. J. Epidemiol.158(4), 337–346 (2003).
   PubMed Web of Science ®Google Scholar
• Kang JH, Pasquale LR, Rosner BA et al. Prospective study of cigarette smoking and the risk of primary open-angle glaucoma. Arch. Ophthalmol.121(12), 1762–1768 (2003).
   PubMedGoogle Scholar
• Kang JH, Pasquale LR, Willett WC et al. Dietary fat consumption and primary open-angle glaucoma. Am. J. Clin. Nutr.79(5), 755–764 (2004).
   PubMed Web of Science ®Google Scholar
• Wang C, Bowen DJ, Kardia SL. Research and practice opportunities at the intersection of health education, health behavior, and genomics. Health Educ. Behav.32(5), 686–701 (2005).
   PubMed Web of Science ®Google Scholar
• Hudson KL, Holohan MK, Collins FS. Keeping pace with the times– the Genetic Information Nondiscrimination Act of 2008. N. Engl. J. Med.358(25), 2661–2663 (2008).
   PubMed Web of Science ®Google Scholar
• Schwarz UI, Ritchie MD, Bradford Y et al. Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med.358(10), 999–1008 (2008).
   PubMed Web of Science ®Google Scholar
• Flockhart DA, O’Kane D, Williams MS et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet. Med.10(2), 139–150 (2008).
   PubMed Web of Science ®Google Scholar
• Bruno C, Fisher G, Moroi S. Is ‘scarless wound healing’ applicable to glaucoma surgery? Expert. Rev. Ophthalmol.2(1), 79–90 (2007).
   Google Scholar
• Drummond MF, Schwartz JS, Jonsson B et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int. J. Technol. Assess. Health. Care.24(3), 244–258; discussion 362–248 (2008).
   PubMed Web of Science ®Google Scholar
• Tunis SR, Pearson SD. Coverage options for promising technologies: Medicare’s ‘coverage with evidence development’. Health Aff. (Millwood)25(5), 1218–1230 (2006).
   PubMed Web of Science ®Google Scholar
• Zhao YY, Takahashi M, Gu JG et al. Functional roles of N-glycans in cell signaling and cell adhesion in cancer. Cancer Sci.99(7), 1304–1310 (2008).
   PubMed Web of Science ®Google Scholar
• Rabut G, Peter M. Function and regulation of protein neddylation. ‘Protein Modifications: Beyond the Usual Suspects’ Review Series. EMBO Rep. (2008).
   Google Scholar
• Meinnel T, Giglione C. Protein lipidation meets proteomics. Front. Biosci.13, 6326–6340 (2008).
   PubMed Web of Science ®Google Scholar
• Hyder CL, Pallari HM, Kochin V, Eriksson JE. Providing cellular signposts – post-translational modifications of intermediate filaments. FEBS Lett.582(14), 2140–2148 (2008).
   PubMed Web of Science ®Google Scholar